Check out which companies are making headlines before the bell:
Jarden (NYSE: JAH) – The consumer goods company will combine with Newell Rubbermaid (NYSE: NWL) in a deal which will see Jarden shareholders receive $21 per share in cash and 0.862 shares of the new company for each share they now hold. Based on Friday's closing prices, the deal is worth $60.03 per share, compared to Jarden's Friday close of $52.68. The combined company will be known as "Newell Brands."
Kimberly-Clark (NYSE: KMB) – Goldman Sachs upgraded the stock to "buy" from "neutral" and added it to its "Conviction Buy" list, pointing to resilient organic sales growth and a favorable cost structure for the consumer products maker.
Coach (NYSE: COH) – Piper Jaffray upgraded the luxury goods maker to "overweight" from "neutral," saying new products are helping drive near-term improvement although Piper said it may be early in making this particular call.
Square (NYSE: SQ) – JPMorgan Chase began coverage of the mobile payment technology provider with an "overweight" rating. Among other factors, JPMorgan points to Square's advantage of having roots in new technology in a legacy-heavy industry.
Hewlett-Packard Enterprise (NYSE: HPE) – Credit Suisse upgraded the stock to "outperform" from "neutral," saying that despite challenging conditions in HPE's traditional enterprise market, it is managing a market transition effectively by increasing its presence in cloud-based solutions.
Tesla (NASDAQ: TSLA) – JPM Securities began coverage on the electric car maker with a "market perform" rating, noting that while Tesla is a trend-setting, disruptive standard bearer in a relatively new industry, it also faces tough competition going forward.
Trina Solar (NYSE: TSL) – The solar company received a buyout offer of $11.60 per share from chairman and CEO Jifan Gao and Shanghai Xingsheng, a subsidiary of China-based Industrial Bank Co. That represents a more than 21 percent premium over the most recent closing price.
GoPro (NASDAQ: GPRO) – The high definition camera maker's stock was downgraded to "underweight" from "equal-weight" at Morgan Stanley, which also cut its price target nearly in half to $12 from $23. The firm points to persistent high inventory issues and slower consumer opportunity in the drone segment, among other factors.
AstraZeneca (London Stock Exchange: AZN-GB) – The European drug maker said it was in talks to buy privately held biotech firm Acerta Pharma. Analysts value the potential deal — aimed at building AstraZeneca's cancer drug portfolio — at more than $5 billion.